| Pathfinder, LLC and SyntheMed, Inc. Complete Merger - MarketWatch (press release) |
|
|
MarketWatch (press release) In preclinical studies, PCs demonstrate the unique ability to reverse cell damage caused by diabetes, renal diseases and myocardial infarction. They may also be effective in other diseases characterized by organ-specific cellular damage. |